Corbin Davis
Authored Items
By Corbin Davis
February 2020, Vol 10, No 2
According to results from a retrospective analysis of nearly 12,000 patients with cancer, increased social support may function as an analgesic and help to mitigate pain. Read Article ›
By Corbin Davis
February 2020, Vol 10, No 2
Reducing pain without increasing opioids is feasible in patients with advanced cancer, according to results presented at the 2019 ASCO Supportive Care in Oncology Symposium. In a retrospective analysis of 300 patients with advanced cancer receiving inpatient palliative care services, researchers found that nearly half of patients who achieved clinically improved pain did so without an increase in oral morphine equivalent daily dose. Read Article ›
By Corbin Davis
January 2020, Vol 10, No 1
Steroids plus exercise could be the best combination for treating fatigue in patients with advanced cancer, according to data presented at the 2019 Supportive Care in Oncology Symposium. Read Article ›
By Corbin Davis
January 2020, Vol 10, No 1
There is no shortage of research on psychosocial issues in patients with cancer, but implementation of this evidence in clinical practice has a long way to go, according to data presented at the 2019 Supportive Care in Oncology Symposium. Read Article ›
By Corbin Davis
December 2019, Vol 9, No 12
Cannabis has been credited as a medicinal plant with benefits ranging from pain and inflammation relief to epileptic seizure reduction to insomnia and anxiety cures, but the evidence is still limited, particularly in the setting of advanced cancer. Read Article ›
By Corbin Davis
March 2018, Vol 8, No 3
Despite major advances in treatment interventions, multiple myeloma remains incurable in the majority of patients, and relapse is an expected part of the disease course. At the 2017 NCCN Hematologic Malignancies Congress, Natalie S. Callander, MD, a hematologist at the University of Wisconsin Carbone Cancer Center, Madison, outlined issues in the management of relapsed or refractory multiple myeloma. Read Article ›
By Corbin Davis
December 2017, Vol 7, No 12
With 5-year survival rates for Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) at 86% and 71%, respectively, the number of lymphoma survivors is on the rise, but achieving long-term quality of life after treatment has ended remains a challenge. Data presented at the 2017 NCCN Hematologic Malignancies Congress reveal that treatment-related side effects cause long-term metabolic, endocrine, physical, and mental alterations that impair functional capacity. Read Article ›
By Corbin Davis
December 2017, Vol 7, No 12
Recent advances in the treatment of patients with multiple myeloma have dramatically altered the trajectory of the disease, as providers now have several efficacious agents in various drug classes at their disposal. At the 2017 NCCN Hematologic Malignancies Congress, Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN, provided management strategies for newly diagnosed multiple myeloma, including the role of autologous stem-cell transplant (ASCT) and posttransplant maintenance therapy. Read Article ›
By Corbin Davis
March 2016, Vol 6, No 3
Given the high cost of care for acute leukemia, innovative payment strategies that reward longitudinal care and create economic incentives for data-driven care delivery are needed, according to Joseph Alvarnas, MD, Director of Value-Based Analytics, and Associate Clinical Professor of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA. Read Article ›